L-carnitine prevents lenvatinib-induced muscle toxicity without impairment of the anti-angiogenic efficacy

Lenvatinib is an oral tyrosine kinase inhibitor that acts on multiple receptors involved in angiogenesis. Lenvatinib is a standard agent for the treatment of several types of advanced cancers; however, it frequently causes muscle-related adverse reactions. Our previous study revealed that lenvatinib...

Descripción completa

Detalles Bibliográficos
Autores principales: Jing, Zheng, Iba, Tomohiro, Naito, Hisamichi, Xu, Pingping, Morishige, Jun-ichi, Nagata, Naoto, Okubo, Hironao, Ando, Hitoshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10116043/
https://www.ncbi.nlm.nih.gov/pubmed/37089945
http://dx.doi.org/10.3389/fphar.2023.1182788

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10116043/
https://www.ncbi.nlm.nih.gov/pubmed/37089945
http://dx.doi.org/10.3389/fphar.2023.1182788

Ejemplares similares